Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.…
Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 0.2449 USD on 20 November 2026. Its 52-week range is 0.1687 USD to 98.20 USD: the price is 99.8% below the high and 45.2% above the low.
Its market capitalisation is 2.19M USD.
Lakewood-Amedex Biotherapeutics reports return on equity of 195.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.25M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.